Literature DB >> 32006166

Differentiation of supratentorial single brain metastasis and glioblastoma by using peri-enhancing oedema region-derived radiomic features and multiple classifiers.

Fei Dong1, Qian Li2, Biao Jiang1, Xiuliang Zhu1, Qiang Zeng3, Peiyu Huang1, Shujun Chen4, Minming Zhang5.   

Abstract

OBJECTIVE: To differentiate supratentorial single brain metastasis (MET) from glioblastoma (GBM) by using radiomic features derived from the peri-enhancing oedema region and multiple classifiers.
METHODS: One hundred and twenty single brain METs and GBMs were retrospectively reviewed and then randomly divided into a training data set (70%) and validation data set (30%). Quantitative radiomic features of each case were extracted from the peri-enhancing oedema region of conventional MR images. After feature selection, five classifiers were built. Additionally, the combined use of the classifiers was studied. Accuracy, sensitivity, and specificity were used to evaluate the classification performance.
RESULTS: A total of 321 features were extracted, and 3 features were selected for each case. The 5 classifiers showed an accuracy of 0.70 to 0.76, sensitivity of 0.57 to 0.98, and specificity of 0.43 to 0.93 for the training data set, with an accuracy of 0.56 to 0.64, sensitivity of 0.39 to 0.78, and specificity of 0.50 to 0.89 for the validation data set. When combining the classifiers, the classification performance differed according to the combined mode and the agreement pattern of classifiers, and the greatest benefit was obtained when all the classifiers reached agreement using the same weight and simple majority vote method.
CONCLUSIONS: Three features derived from the peri-enhancing oedema region had moderate value in differentiating supratentorial single brain MET from GBM with five single classifiers. Combined use of classifiers, like multi-disciplinary team (MDT) consultation, could confer extra benefits, especially for those cases when all classifiers reach agreement. KEY POINTS: • Radiomics provides a way to differentiate single brain MET between GBM by using conventional MR images. • The results of classifiers or algorithms themselves are also data, the transformation of the primary data. • Like MDT consultation, the combined use of multiple classifiers may confer extra benefits.

Entities:  

Keywords:  Diagnosis; Glioblastoma; Machine learning; Neoplasm metastasis; Radiomics

Mesh:

Year:  2020        PMID: 32006166     DOI: 10.1007/s00330-019-06460-w

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  11 in total

Review 1.  Machine Learning-Based Radiomics in Neuro-Oncology.

Authors:  Felix Ehret; David Kaul; Hans Clusmann; Daniel Delev; Julius M Kernbach
Journal:  Acta Neurochir Suppl       Date:  2022

Review 2.  A Systematic Review of the Current Status and Quality of Radiomics for Glioma Differential Diagnosis.

Authors:  Valentina Brancato; Marco Cerrone; Marialuisa Lavitrano; Marco Salvatore; Carlo Cavaliere
Journal:  Cancers (Basel)       Date:  2022-05-31       Impact factor: 6.575

3.  Machine learning based differentiation of glioblastoma from brain metastasis using MRI derived radiomics.

Authors:  Sarv Priya; Yanan Liu; Caitlin Ward; Nam H Le; Neetu Soni; Ravishankar Pillenahalli Maheshwarappa; Varun Monga; Honghai Zhang; Milan Sonka; Girish Bathla
Journal:  Sci Rep       Date:  2021-05-18       Impact factor: 4.379

4.  Exploring MRI Characteristics of Brain Diffuse Midline Gliomas With the H3 K27M Mutation Using Radiomics.

Authors:  Qian Li; Fei Dong; Biao Jiang; Minming Zhang
Journal:  Front Oncol       Date:  2021-05-24       Impact factor: 6.244

5.  An Integrated Radiomics Model Incorporating Diffusion-Weighted Imaging and 18F-FDG PET Imaging Improves the Performance of Differentiating Glioblastoma From Solitary Brain Metastases.

Authors:  Liqiang Zhang; Rui Yao; Jueni Gao; Duo Tan; Xinyi Yang; Ming Wen; Jie Wang; Xiangxian Xie; Ruikun Liao; Yao Tang; Shanxiong Chen; Yongmei Li
Journal:  Front Oncol       Date:  2021-08-30       Impact factor: 6.244

6.  Differentiating solitary brain metastases from glioblastoma by radiomics features derived from MRI and 18F-FDG-PET and the combined application of multiple models.

Authors:  Xu Cao; Duo Tan; Zhi Liu; Meng Liao; Yubo Kan; Rui Yao; Liqiang Zhang; Lisha Nie; Ruikun Liao; Shanxiong Chen; Mingguo Xie
Journal:  Sci Rep       Date:  2022-04-06       Impact factor: 4.379

Review 7.  Beyond Glioma: The Utility of Radiomic Analysis for Non-Glial Intracranial Tumors.

Authors:  Darius Kalasauskas; Michael Kosterhon; Naureen Keric; Oliver Korczynski; Andrea Kronfeld; Florian Ringel; Ahmed Othman; Marc A Brockmann
Journal:  Cancers (Basel)       Date:  2022-02-07       Impact factor: 6.639

8.  Single brain metastasis versus glioblastoma multiforme: a VOI-based multiparametric analysis for differential diagnosis.

Authors:  Andrea Romano; Giulia Moltoni; Alessia Guarnera; Luca Pasquini; Alberto Di Napoli; Antonio Napolitano; Maria Camilla Rossi Espagnet; Alessandro Bozzao
Journal:  Radiol Med       Date:  2022-03-22       Impact factor: 6.313

9.  Predicting Adverse Radiation Effects in Brain Tumors After Stereotactic Radiotherapy With Deep Learning and Handcrafted Radiomics.

Authors:  Simon A Keek; Manon Beuque; Sergey Primakov; Henry C Woodruff; Avishek Chatterjee; Janita E van Timmeren; Martin Vallières; Lizza E L Hendriks; Johannes Kraft; Nicolaus Andratschke; Steve E Braunstein; Olivier Morin; Philippe Lambin
Journal:  Front Oncol       Date:  2022-07-13       Impact factor: 5.738

Review 10.  Machine Learning Applications for Differentiation of Glioma from Brain Metastasis-A Systematic Review.

Authors:  Leon Jekel; Waverly R Brim; Marc von Reppert; Lawrence Staib; Gabriel Cassinelli Petersen; Sara Merkaj; Harry Subramanian; Tal Zeevi; Seyedmehdi Payabvash; Khaled Bousabarah; MingDe Lin; Jin Cui; Alexandria Brackett; Amit Mahajan; Antonio Omuro; Michele H Johnson; Veronica L Chiang; Ajay Malhotra; Björn Scheffler; Mariam S Aboian
Journal:  Cancers (Basel)       Date:  2022-03-08       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.